EVP, Head of Technical Operations Micron Biomedical, Inc
In this presentation, we will discuss the development of Micron Biomedical's dissolving microneedle technology for measles-rubella vaccination with an emphasis on preclinical and clinical data generated to date including the first-ever microneedle trial in children. In this Phase 1/2 trial, Micron’s dissolving microneedle technology was used to successfully deliver a measles-rubella vaccine to adults, toddlers, and infants. Safety, immunogenicity, and acceptability results from the trial will be discussed.
Learning Objectives:
Upon completion, participants will be able to understand what preclinical tests are used in the development of novel microneedle systems to support clinical development
Upon completion, participants will be able to compare the safety, immunogenicity, and acceptability of microneedle technology for measles-rubella vaccination to standard subcutaneous injection
Upon completion, participants will be able to discuss product attributes that render microneedle technology well suited to increase vaccination coverage in low and middle income countries
